Clinical Trials on Hepatitis Delta Virus in South Africa

Total 1573 results

bioLytical Laboratories

Recruiting

Trial of Hepatitis C Self-Testing in the Hands of Untrained Lay Users

Hepatitis C

South Africa
bioLytical Laboratories

Recruiting

Diagnostic Sensitivity and Specificity of iStatis HBsAg Test at the Point-Of-Care Site Settings

Hepatitis B | Hepatitis B Infection

South Africa
University of Witwatersrand, South Africa

Unknown

Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine (MV/VV/Hep-AV)

Measles | Hepatitis A | Varicella

South Africa
GlaxoSmithKline

Completed

Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth

Diphtheria; Haemophilus Influenzae Type b; Hepatitis B; Tetanus; Whole Cell Pertussis

South Africa
Sanofi Pasteur, a Sanofi Company

Completed

DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants

Hepatitis B | Pertussis | Tetanus | Diphtheria | Polio | Human Immunodeficiency Virus Infection

South Africa
Sanofi

Completed

Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine

Hepatitis B | Whooping Cough | Tetanus | Diphtheria | Poliomyelitis

South Africa
Sanofi Pasteur, a Sanofi Company

Completed

Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV

Hepatitis B | Pertussis | Diphtheria | Polio | Haemophilus Influenzae Type b

South Africa
Vaxine Pty Ltd
Australian Respiratory and Sleep Medicine Institute

Not yet recruiting

A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection (HBV003)

Chronic Hepatitis b

Australia
AbbVie

Completed

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection (ENDURANCE-5 6)

Hepatitis C Virus (HCV)

United States, Australia, Belgium, Canada, France, New Zealand, Singapore, South Africa, Vietnam
Kirby Institute
Janssen-Cilag Ltd.

Completed

DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C) (DARE-C)

Hepatitis C, Chronic

Australia
Kirby Institute

Completed

A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use (SIMPLIFY)

Hepatitis C

Australia
Kirby Institute

Completed

Treatment of Recently Acquired Hepatitis C Virus Infection (ATAHC-II)

Acute Hepatitis C

Australia
University of North Carolina, Chapel Hill
National Institute on Drug Abuse (NIDA); National Institute on Alcohol Abuse... and other collaborators

Completed

Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth

HIV Infection | Hepatitis B

Brazil, United States, South Africa
Kirby Institute
The University of New South Wales

Completed

Australian Trial in Acute Hepatitis C Recall Study (ATAHC Recall)

Acute Hepatitis C

Australia
Kirby Institute

Completed

Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting (SHARP-P)

Hepatitis C, Chronic

Australia
Enyo Pharma
CPR Pharma Services Pty Ltd, Australia

Completed

Drug Drug Interaction Study for EYP001 With Entecavir

Hepatitis B, Chronic

Australia
GlaxoSmithKline

Completed

To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPV

Rotavirus Infections

South Africa
TetraLogic Pharmaceuticals

Terminated

Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B

Hepatitis B

Australia
Kirby Institute

Completed

A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection (D3FEAT)

Hepatitis C, Chronic

Australia
Kirby Institute

Completed

Hepatitis B Acceptability and Vaccination Incentive Trial (HAVIT)

Hepatitis B

Australia
Kirby Institute

Completed

Direct-acting Antiviral Therapy and Reinfection Among PWID With Chronic HCV in Community-based Settings (SHARP-C)

Hepatitis C, Chronic

Australia
GlaxoSmithKline

Completed

A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single & Repeat Escalating Doses of GSK2878175 in Healthy Subjects

Hepatitis C, Chronic

Australia
Vaxine Pty Ltd
Flinders Medical Centre

Completed

Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine

Exposure to Hepatitis B Virus

Australia
Kirby Institute
Bristol-Myers Squibb

Withdrawn

Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism (HEPCOG-II)

Hepatitis C, Chronic

Australia
Bavarian Nordic

Completed

Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years

Measles

South Africa
Kirby Institute

Recruiting

Real World Assessment of People Living With Chronic Hepatitis B in Australia (REACH-B)

Hepatitis B

Australia
Emory University
National Institute of Mental Health (NIMH); University of KwaZulu

Recruiting

Support for Adolescents Living With HIV in South Africa (InTSHA VIP)

HIV | Human Immunodeficiency Virus

South Africa
Kirby Institute

Recruiting

Evaluation of Hepatitis B Virus (HBV) DNA Test as Point of Care Tool (HBVPOCT)

Hepatitis B

Australia
GlaxoSmithKline

Completed

Long Term F/U Studies at Y5&6 to Demonstrate the Equivalence of 2 Vaccination Schedules of Combined Hepatitis A & B Vaccine

Hepatitis B | Hepatitis A

Australia
GlaxoSmithKline

Completed

Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females

Infections, Papillomavirus

South Africa
Kirby Institute
Justice Health & Forensic Mental Health Network NSW Australia

Completed

Prisons Evaluation of a One-stop-shop InterVentiOn (PIVOT)

Hepatitis C

Australia
Kirby Institute

Recruiting

Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir (STRIVE-4)

Hepatitis C

Australia
Kirby Institute

Withdrawn

Evaluation of Novel Point of Care Hepatitis B Diagnostic Assays

Hepatitis B

Australia
Bristol-Myers Squibb

Withdrawn

Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients

Chronic Hepatitis C

Australia
Boehringer Ingelheim

Withdrawn

Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients

Hepatitis C, Chronic

Australia, Spain, Sweden
Montefiore Medical Center
National Institute on Drug Abuse (NIDA); Prisma Health-Upstate

Recruiting

Advanced Care Coordination and Enhanced Linkage and Retention Among Transitional Re-Entrants (ACCELERATE)

Hepatitis C

United States
Kirby Institute
Merck Sharp & Dohme LLC; The University of New South Wales

Completed

Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients (SEARCH-C)

Chronic Hepatitis C Infection

Australia
Kirby Institute
Flinders University; South Australian Health and Medical Research Institute

Recruiting

Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination (SCALE-C)

Liver Diseases | Digestive System Diseases | RNA Virus Infections | Hepatitis | Hepatitis, Viral, Human | Hepatitis C

Australia
GlaxoSmithKline

Completed

Challenge Dose of Hepatitis B Vaccine in Subjects Who Previously Received Engerix™-B Vaccine

Hepatitis B

Australia, Belgium
Kirby Institute

Completed

A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams (TEMPO)

Hepatitis C

Australia
Bristol-Myers Squibb

Completed

Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection

Hepatitis B Infection

United States, Mexico, Puerto Rico, Brazil, South Africa
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older

Influenza

South Africa
Kirby Institute

Completed

DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral) (DARE-C II)

Hepatitis C

Australia, New Zealand
Inovio Pharmaceuticals

Completed

Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects

Hepatitis B

Australia, Taiwan, United States, Singapore, New Zealand, Hong Kong, Thailand, Philippines
GlaxoSmithKline

Completed

Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs

Hepatitis B

Belgium, Ukraine, Australia
Prisma Health-Upstate

Completed

HCV-Smoking Cessation Study

Smoking Cessation | Hepatitis C

United States
Garvan Institute of Medical Research

Completed

Chronic Hepatitis C and Insulin Resistance

Hepatitis C | Insulin Resistance

Australia
University of North Carolina, Chapel Hill
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Innovations in HIV Testing (TI)

Human Immunodeficiency Virus

South Africa
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)

Completed

HIV & Drug Abuse Prevention for South African Men

Substance-Related Disorders | Alcoholism | Human Immunodeficiency Virus

South Africa
University of North Carolina, Chapel Hill
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Efficacy of HIV Post-Test Support for ANC in South Africa (SAHAPS)

Acquired Immunodeficiency Syndrome | HIV

South Africa

Clinical Trials on Hepatitis Delta Virus in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Azerbaijan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations